JCR to License Lysosome Storage Disease Treatment to Global Player by March 2020: Chairman

JCR Chairman and President Shin Ashida JCR Pharmaceuticals is likely to out-license its lysosomal storage disease treatment to a global pharma player within this fiscal year ending March 2020, Chairman and President Shin Ashida has revealed. “We reckon a license...read more